Financial Performance - Operating revenue for the period was ¥382,585,206.31, representing a significant increase of 149.05% year-on-year[4] - Net profit attributable to shareholders was ¥96,992,749.11, a turnaround from a loss of ¥24,855,428.82 in the same period last year[4] - Basic earnings per share for the period was ¥0.55, compared to a loss of ¥0.14 per share in the previous year[4] - The company reported a total of ¥3,984,796.31 in non-recurring gains and losses for the period[5] - The company achieved operating revenue of RMB 382.59 million, an increase of RMB 228.97 million or 149.05% compared to the same period last year[11] - The net profit attributable to shareholders was RMB 96.99 million, a turnaround from a loss of RMB 24.86 million in the same period last year[12] - Total operating revenue for Q1 2021 reached RMB 382,585,206.31, a significant increase from RMB 153,614,830.20 in Q1 2020, representing a growth of 149.5%[20] - Net profit for Q1 2021 was RMB 99,315,085.73, compared to a net loss of RMB 28,408,114.30 in Q1 2020, indicating a turnaround in profitability[20] - The company reported a basic earnings per share of RMB 0.55 for Q1 2021, compared to a loss per share of RMB -0.14 in Q1 2020[21] - Total comprehensive income for Q1 2021 was RMB 120,373,389.52, a significant recovery from a loss of RMB -80,366,877.89 in Q1 2020[21] Cash Flow - Net cash flow from operating activities was ¥15,609,445.06, a significant improvement from a negative cash flow of ¥54,461,823.95 in the same period last year[4] - Cash flow from operating activities totaled RMB 375,765,049.92 in Q1 2021, compared to RMB 270,287,164.05 in Q1 2020, showing improved cash generation[24] - In Q1 2021, the net cash flow from operating activities was -30,284,718.27, compared to -28,836,899.02 in Q1 2020, indicating a decline in operational cash flow[26] - The total cash inflow from investment activities was 68,757,274.04, up from 32,979,522.42 in the same period last year, reflecting an increase in investment returns[26] - The net cash flow from investment activities was -190,312,463.07, significantly worse than -43,738,637.18 in Q1 2020, highlighting increased investment expenditures[26] - The total cash flow for the period showed a net decrease of -222,592,297.29, compared to -72,714,182.45 in Q1 2020, reflecting overall financial strain[26] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,402,802,145.37, an increase of 1.65% compared to the end of the previous year[4] - Current assets totaled ¥3,770,803,864.17, slightly down from ¥3,809,958,571.16 at the end of 2020, indicating a decrease of about 1.02%[16] - Non-current assets increased to ¥2,631,998,281.20 from ¥2,488,746,817.00, reflecting a growth of approximately 5.73%[16] - Total liabilities decreased to ¥547,186,310.43 from ¥564,462,942.74, showing a reduction of approximately 3.06%[17] - Shareholders' equity increased to ¥5,855,615,834.94 from ¥5,734,242,445.42, representing a growth of about 2.11%[17] - The company reported an increase in accounts receivable to ¥365,695,416.59 from ¥333,527,490.76, which is an increase of approximately 9.63%[16] - Inventory levels rose slightly to ¥258,395,227.48 from ¥255,126,944.53, indicating a growth of about 0.89%[16] Research and Development - Research and development expenses accounted for 9.55% of operating revenue, a decrease of 8.91 percentage points from the previous year[4] - Research and development expenses amounted to RMB 36.53 million, representing a growth of 28.82% year-on-year[13] - Research and development expenses increased to RMB 36,527,079.45 in Q1 2021, up from RMB 28,354,664.31 in Q1 2020, reflecting a focus on innovation[20] Shareholder Information - The company had a total of 7,411 shareholders at the end of the reporting period[6] - The top shareholder, Jiang Wei, held 25.17% of the shares, totaling 44,449,000 shares[6] Other Financial Metrics - The weighted average return on equity was 1.75%, compared to -0.46% in the previous year[4] - The company reported a significant decrease in other income by 52.45% to RMB 4.75 million, attributed to reduced government subsidies compared to the previous year[11] - The company recorded investment income of RMB 13,750,368.57 in Q1 2021, a significant increase from RMB 3,351,610.11 in Q1 2020, indicating better investment performance[20] - Sales expenses rose to RMB 122,111,278.28 in Q1 2021, compared to RMB 114,868,235.77 in Q1 2020, indicating increased investment in sales efforts[20] - The company reported a total operating cost of RMB 284,719,567.04 in Q1 2021, up from RMB 193,029,975.02 in Q1 2020, reflecting higher operational expenses[20]

2020 年報 | | | | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 5 | 主席致辭 | | 7 | 管理層討論與分析 | | 24 | 董事會報告 | | 46 | 企業管治報告 | | 67 | 企業社會責任 | | 69 | 董事、監事及高級管理人員簡介 | | 78 | 獨立核數師報告 | | 84 | 綜合損益及其他綜合收益表 | | 86 | 綜合財務狀況表 | | 88 | 綜合權益變動表 | | 90 | 綜合現金流量表 | | 93 | 財務報表附註 | | 185 | 釋義 | | 188 | 技術詞彙 | 公司資料 第四屆董事會 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 獨立非執行董事： 李穎琦女士 姜志宏先生 蘇治先生 楊玉社先生 趙磊先生 第四屆監事會 劉遠中先生 （主席） 楊青女士 唐躍軍先生 魏長征先生 楊林鋒先生 授權代表 黃明先生 趙明璟先生 聯席公司秘書 田敏女士 趙明璟先生 （香港特許秘書公會資深會員） 審計委員會 李穎琦女士（ 主席） 游捷 ...

Financial Performance - The company's operating revenue for 2020 was approximately CNY 1.33 billion, a decrease of 16.95% compared to 2019[12]. - The net profit attributable to shareholders for 2020 was approximately CNY 230 million, down 37.95% from the previous year[12]. - The net profit after deducting non-recurring gains and losses was approximately CNY 206 million, a decrease of 42.25% compared to 2019[12]. - The basic earnings per share for 2020 was CNY 1.30, a decline of 42.73% from 2019[13]. - The company's total assets at the end of 2020 were approximately CNY 6.30 billion, an increase of 2.39% from the end of 2019[12]. - The company's net assets attributable to shareholders at the end of 2020 were approximately CNY 5.49 billion, an increase of 0.66% from the end of 2019[12]. - The company reported a quarterly revenue of CNY 440 million in Q4 2020, showing a positive trend in the latter half of the year[15]. - The company experienced a net loss of approximately CNY 25 million in Q1 2020, indicating challenges at the beginning of the year[15]. - The company achieved a total revenue of RMB 133,145.11 million in 2020, a decrease of RMB 27,087.37 million or 16.91% compared to the previous year[59]. - The overall gross margin for the company was 74.91% in 2020, down from 77.28% in 2019, primarily due to a significant decrease in revenue from high-margin hyaluronic acid products[59]. Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 88,311,050 RMB, which accounts for 38.38% of the net profit attributable to shareholders for 2020[2]. - In 2020, the company distributed cash dividends of 7.00 RMB per 10 shares, totaling 124,044,620.00 RMB, which accounted for 33.46% of the net profit attributable to shareholders[155]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.49% in 2020, up from 7.24% in 2019[13]. - The R&D expenses for the reporting period amounted to CNY 126.47 million, an increase of CNY 10.40 million, representing a growth rate of 8.96%[42]. - The company has increased its R&D investment to enhance new technology and product development, focusing on collaboration with universities and research institutions[34]. - The company has established a comprehensive R&D system with 270 R&D personnel, accounting for 19.65% of total employees[119]. - The company is actively collaborating with domestic and international universities and research institutions to enhance its R&D capabilities and technology transfer[123]. Market Position and Product Lines - The company has established four major product lines in ophthalmology, medical aesthetics, wound care, and orthopedics, focusing on innovative medical products[19]. - The company is a leading domestic manufacturer of ophthalmic viscoelastic devices and intraocular lenses, with a complete product portfolio covering various materials and optical designs[19]. - The company is the largest domestic producer of orthopedic joint cavity viscoelastic supplements, with a complete range of hyaluronic acid injection products[23]. - The company is the largest producer of surgical anti-adhesion agents in China, with a market share of 29.64% in 2019, maintaining the top position for 13 consecutive years[32]. - The company holds a 45.85% market share in the domestic ophthalmic viscoelastic agent market and nearly 30% in the artificial lens market[64]. Compliance and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has not violated decision-making procedures for external guarantees[3]. - There are no special arrangements for corporate governance[3]. - The company has committed to measures to compensate for any dilution of immediate returns since April 3, 2019, which is also valid for the long term[166]. Environmental Management - The company reported a total wastewater discharge of 76,092 tons and managed to keep all pollutant emissions within regulatory limits during the reporting period[198]. - The company processed 31.5259 tons of general waste and 44.6409 tons of hazardous waste, demonstrating its commitment to environmental management[198]. - The company has implemented effective waste treatment methods, ensuring compliance with environmental regulations for both wastewater and air emissions[199]. - The company has completed the construction of environmental protection facilities, including wastewater treatment and air emission terminal treatment facilities[200]. Strategic Initiatives - The company aims to enhance the quality of life for Chinese citizens and promote patient recovery, focusing on differentiated development in ophthalmology, aesthetic medicine, orthopedics, and surgery[149]. - The company is actively pursuing investment and acquisition opportunities in the global ophthalmic field to accelerate the localization of the Chinese ophthalmic industry[66]. - The company has established a strategic goal to become a leading domestic and internationally recognized biopharmaceutical enterprise in the field of biomedical materials[150]. - The company will integrate acquired businesses to maximize synergies and improve operational efficiency[151].

Financial Performance - Net profit attributable to shareholders was CNY 112,646,895.39, down 55.13% year-on-year[5] - Operating revenue for the first nine months was CNY 892,155,592.36, representing a decline of 22.06% compared to the same period last year[5] - Basic earnings per share were CNY 0.63, down 59.87% from the previous year[6] - The company reported a total revenue of RMB 892.16 million for the current period, a decrease of RMB 252.55 million or 22.06% compared to the same period last year[16] - The main business revenue was RMB 891.25 million, down RMB 251.71 million or 22.02% year-on-year[16] - The ophthalmology product line generated revenue of RMB 381.80 million, accounting for 42.84% of total revenue, a decrease of 23.88% from the previous year[16] - The orthopedic product line revenue was RMB 224.61 million, representing 25.20% of total revenue, down 11.12% year-on-year[16] - The company reported a total operating cost of ¥317,248,919.13 for Q3 2020, compared to ¥299,886,373.78 in Q3 2019, indicating an increase of approximately 5.5%[27] - The company reported a total comprehensive income of ¥21,558,659.11 for Q3 2020, compared to ¥9,375,995.01 in Q3 2019, indicating an increase of approximately 130%[30] Cash Flow and Investments - The net cash flow from operating activities was CNY 110,051,983.31, a decrease of 45.17% year-on-year[5] - The company reported a net cash outflow from investing activities of CNY -381,425,700.69, primarily due to new investment agreements[20] - The company’s total cash outflow from operating activities was 308,036,938.41 RMB, slightly lower than 310,538,577.16 RMB in the same period of 2019[33] - The company reported a significant decrease in cash received from other operating activities, totaling 12,128,171.10 RMB, down from 25,591,020.00 RMB in the same period of 2019[33] - The company experienced a net cash outflow from investment activities of -53,687,241.10 RMB, compared to a positive cash flow of 68,443,479.99 RMB in the prior year[34] - Cash and cash equivalents at the end of the period stood at 303,326,921.67 RMB, down from 46,332,226.90 RMB in the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,145,082,708.57, a decrease of 0.11% compared to the end of the previous year[5] - The total liabilities increased to CNY 558,874,882.17 from CNY 498,516,864.48 at the end of 2019[23] - The company reported a decrease in accounts receivable to CNY 316,448,358.65 from CNY 381,990,938.69 year-on-year[22] - The company’s total liabilities as of September 30, 2020, were ¥320,395,320.67, compared to ¥177,729,022.12 in the previous year, showing a significant increase[26] - The total equity attributable to shareholders decreased to ¥4,152,760,978.36 from ¥4,287,888,951.10 at the end of 2019[26] Research and Development - Research and development expenses accounted for 9.43% of operating revenue, an increase of 2.49 percentage points compared to the previous year[6] - Research and development expenses for Q3 2020 were ¥27,529,488.77, slightly down from ¥28,105,188.21 in Q3 2019[27] - Research and development expenses for Q3 2020 were ¥8,615,954.67, a decrease from ¥11,799,584.47 in Q3 2019, representing a reduction of about 27%[29] Market and Product Development - The company anticipates a recovery in domestic business, with major product lines showing positive growth trends in the third quarter[17] - The company plans to continue expanding its product offerings and market presence through strategic initiatives and product differentiation[18] - The launch of the third-generation hyaluronic acid product "Hai Mei" occurred on August 7, 2020, aimed at consolidating the company's leadership in the domestic hyaluronic acid market[18] - The company successfully participated in bulk procurement for high-value medical consumables in various provinces, enhancing market share for its intraocular lens products[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,567[8]

Financial Performance - For the six months ended June 30, 2020, the company recorded revenue of approximately RMB 493.61 million, a decrease of approximately RMB 287.00 million or 36.8% compared to RMB 780.61 million in the same period of 2019[7]. - The profit attributable to ordinary equity holders of the company was approximately RMB 27.53 million, down approximately 84.9% from RMB 182.57 million in the same period of 2019[7]. - Basic earnings per share for the period were RMB 0.15, down from RMB 1.14 in the same period of 2019[7]. - The overall gross margin for the reporting period was 77.1%, stable compared to 76.5% in the same period of 2019[11]. - The company reported a net profit for the six months ended June 30, 2020, of RMB 12.11 million, significantly lower than RMB 196.49 million in the prior year[71]. - Total comprehensive income for the period was RMB (32,520,000), reflecting the impact of foreign exchange losses and other comprehensive income adjustments[78]. - The company reported a profit of RMB 182,568 thousand for the period, contributing to total comprehensive income of RMB 202,507 thousand[77]. Revenue Breakdown - Revenue from ophthalmic products was approximately RMB 209.13 million, a decrease of about RMB 134.90 million or 39.2% compared to the same period in 2019[15]. - Revenue from artificial lenses was approximately RMB 116.32 million, down 44.7% compared to the same period in 2019[16]. - Revenue from viscoelastic materials was approximately RMB 63.14 million, a decrease of 19.2% compared to the same period in 2019[16]. - In the aesthetic and wound care segment, the company reported revenue of approximately RMB 75.81 million, a decrease of about 50.7% compared to the same period in 2019, primarily due to the impact of COVID-19[23]. - The orthopedic products generated revenue of approximately RMB 128.92 million, a decrease of about 23.7% compared to the previous year, but showed recovery to nearly 90% of the previous year's revenue in Q2 2020[25]. - Revenue from anti-adhesion and hemostatic products was approximately RMB 68,413 thousand, a decrease of 28.3% compared to RMB 95,468 thousand in the previous year[97]. Research and Development - Research and development expenses amounted to approximately RMB 56.57 million, an increase of approximately RMB 5.25 million or 10.2% compared to RMB 51.32 million in the same period of 2019, with R&D expenses accounting for 11.5% of revenue[7]. - The R&D investment in the ophthalmology product line was approximately RMB 31.88 million, an increase of approximately RMB 7.29 million or 29.6% compared to the previous year, primarily due to multiple ophthalmic projects entering clinical trial stages[7]. - The group is actively developing over ten projects in ophthalmology, with R&D investment in this area amounting to approximately RMB 318.8 million, a 29.6% increase compared to the same period in 2019[32]. - The company is focusing on expanding its ophthalmic business into myopia prevention and refractive correction, addressing a significant market opportunity in China where over 600 million people are myopic[20]. - The company has developed a hydrophobic injection molding process for aspheric intraocular lens products, which has received ethical approval and is set to begin clinical trials[20]. Impact of COVID-19 - The COVID-19 pandemic significantly impacted the company's operations, leading to a temporary halt in many medical services, including ophthalmology outpatient services and elective surgeries[10]. - Revenue across all product lines decreased compared to the same period in 2019, with the first quarter being particularly affected by the pandemic and the Spring Festival holiday[10]. - The second quarter showed signs of gradual recovery as domestic pandemic control measures were effective[10]. - The company is focused on continuing its R&D efforts and adapting to the changing market conditions post-pandemic[10]. Operational Efficiency and Strategy - The company plans to enhance its operational efficiency and core competitiveness through resource integration across R&D, production, sales, and services, particularly focusing on acquired companies[41]. - The company aims to increase R&D investment in innovative products and optimize its product portfolio to maintain a technological lead in ophthalmology, aesthetics, orthopedics, and surgery[41]. - The company is set to launch multiple high-value consumables procurement initiatives, including intraocular lenses, across various provinces and alliances in the second half of 2020[42]. - The company will actively explore new products and indications to achieve synergistic development in its orthopedic product line, solidifying its market leadership in China[46]. Financial Position - The company's current assets totaled approximately RMB 3,827.41 million, a decrease of about RMB 117.96 million compared to the end of 2019[60]. - Current liabilities increased to approximately RMB 504.50 million, up RMB 144.53 million compared to the end of 2019[60]. - The current ratio was approximately 7.59, slightly down from 10.96 at the end of 2019, indicating a stable financial position[60]. - Cash and cash equivalents as of June 30, 2020, were approximately RMB 901.97 million, a decrease of about RMB 42.54 million from RMB 944.51 million as of December 31, 2019[67]. - The company's total liabilities were approximately RMB 651.75 million, resulting in a debt-to-asset ratio of 10.6%, up from 8.1% as of December 31, 2019[67]. Shareholder Information - The board of directors did not recommend the payment of an interim dividend for the six months ended June 30, 2020[8]. - The company declared dividends amounting to RMB 80,023 thousand during the reporting period[77]. - Major shareholders include Jiang Wei, holding 44,449,000 A shares (32.26% of A shares) and 28,800,000 A shares (20.90% of A shares through spouse's interest)[163]. - Prime Capital Management Company Limited holds 4,793,808 H shares, representing approximately 11.97% of the total H shares[167]. Corporate Governance - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[174]. - The company will continue to review and enhance its corporate governance practices to ensure compliance with the Corporate Governance Code[174]. - The audit committee held meetings on March 26, 2020, and April 29, 2020, to review the audited financial statements for the year ended December 31, 2019, and the unaudited financial statements for the three months ended March 31, 2020[175].

Financial Performance - The company reported a significant increase in revenue for the first half of 2020, achieving a total of 1.2 billion RMB, representing a growth of 25% year-over-year[8]. - The company's operating revenue for the first half of the year was ¥495,964,161.43, a decrease of 36.85% compared to the same period last year[14]. - The net profit attributable to shareholders was ¥27,527,226.38, down 84.92% year-on-year[16]. - The net cash flow from operating activities decreased by 69.24% to ¥40,571,127.56 compared to the previous year[16]. - Basic and diluted earnings per share were both ¥0.15, reflecting a decline of 86.84% from the same period last year[15]. - The overall gross profit margin for the reporting period was 77.21%, stable compared to 76.62% in the same period last year[51]. - The company reported a total revenue of 44,275.00 million RMB for the first half of 2020, with a net profit of 3,005.87 million RMB, representing a significant increase in performance[42]. Research and Development - The proportion of R&D investment to operating revenue increased by 4.88 percentage points to 11.41%[15]. - The company continues to focus on R&D in medical materials and technologies, particularly in the fields of ophthalmology and orthopedic treatments[21]. - Research and development expenses for the reporting period amounted to CNY 56,573,002.69, representing an increase of 10.24% compared to the previous year, with R&D expenses accounting for 11.41% of total revenue[39]. - The R&D team consists of 274 personnel, accounting for 19.97% of the total workforce, with an average salary of 125,774.48 RMB[43]. - The company continues to invest in R&D for new technologies and products, collaborating with renowned universities and research institutions[33]. Market Expansion and Product Development - The company has outlined a positive outlook for the second half of 2020, projecting a revenue growth of 30% compared to the first half[8]. - New product development includes the launch of a novel hyaluronic acid injection, expected to contribute an additional 200 million RMB in revenue by the end of the year[8]. - The company is actively pursuing market expansion strategies, targeting new regions in Southeast Asia, with an estimated investment of 100 million RMB for market entry[8]. - The company has established long-term stable partnerships with major medical aesthetic institutions, with its hyaluronic acid products "Haiwei" and "Jiaolan" recognized by consumers, ranking among the top in market share[30]. - The company has increased its market share in orthopedic joint cavity injection products from 39.67% to 42.06% over six years[32]. Financial Integrity and Governance - The company has reported no non-operational fund occupation by controlling shareholders, ensuring financial integrity[4]. - The board has confirmed that there are no significant changes in corporate governance arrangements during the reporting period[4]. - The company has not proposed any profit distribution plan for the reporting period, focusing on reinvestment for growth[4]. - There are no undisclosed related party transactions between the company and its subsidiaries, ensuring compliance with relevant laws and regulations[101]. - The company has pledged to avoid any form of fund occupation from its subsidiaries, maintaining financial integrity[101]. Investment and Acquisitions - The company has completed the acquisition of a biotechnology firm, which is anticipated to enhance its R&D capabilities and add 150 million RMB to annual revenue[8]. - The company has engaged in multiple upstream and downstream acquisitions to enhance its industry chain layout, which may affect goodwill valuation[71]. - The company has filed 13 new invention patent applications during the reporting period, reflecting its commitment to innovation[38]. Challenges and Risks - The company faced significant impacts on sales due to strict pandemic control measures, affecting both domestic and overseas operations[16]. - Increased market competition may impact the company's market share and profitability in the long term[70]. - Regulatory changes in the pharmaceutical and medical device sectors could increase compliance costs and reduce product demand[72]. Environmental and Compliance - The company emphasizes strict compliance with environmental regulations and aims to control and reduce pollutant generation from the source[106]. - The company maintained compliance with environmental regulations, with all pollutants meeting discharge standards and no environmental accidents reported during the reporting period[107]. Shareholder Information - The company reported a total of 164.9 million shares of domestic stock held by major shareholders, with a lock-up period of 36 months from the date of listing on the Shanghai Stock Exchange[99]. - The company has committed to not transferring or entrusting the management of its shares for 12 months post-listing, ensuring stability in shareholding[99]. - The company has a total of 28,800,000 shares held by shareholder You Jie, representing 16.19% of the total shares[125]. Investment Funds and Strategies - The company reported a total of 2,711 million in various investment funds as of April 30, 2020, indicating stable fund management performance[114]. - The investment funds listed include multiple flexible allocation mixed funds, all maintaining a consistent value of 2,711 million, reflecting strong investor confidence[115]. - The company is actively managing its investment strategies to adapt to market conditions, which is essential for maintaining competitive performance[115].

Financial Performance - Operating revenue for the period was CNY 153,614,830.20, representing a decline of 50.81% year-on-year [4]. - Net profit attributable to shareholders was a loss of CNY 24,855,428.82, a decrease of 137.33% compared to the same period last year [4]. - The net cash flow from operating activities was negative CNY 54,461,823.95, a significant decline of 1,450.97% year-on-year [4]. - Basic and diluted earnings per share were both -CNY 0.14, a decrease of 133.33% compared to the same period last year [4]. - The company's net profit attributable to shareholders was CNY -24.86 million, a decline of 137.33% compared to the previous year [15]. - The company reported a significant drop in sales due to the COVID-19 pandemic, with approximately 70% of revenue coming from mainland China [17]. - The company expects a potential significant change in net profit compared to the previous year due to the ongoing impact of the pandemic [22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,014,270,430.54, a decrease of 2.24% compared to the end of the previous year [4]. - Total current assets amounted to ¥2,662,575,569.56, down from ¥2,772,472,546.50, reflecting a decrease of about 4.0% [27]. - Total liabilities decreased to ¥148,211,316.63 from ¥177,729,022.12, indicating a decline of about 16.6% [29]. - Total equity attributable to shareholders decreased to ¥4,280,337,123.60 from ¥4,287,888,951.10, a slight decrease of approximately 0.2% [29]. Revenue Breakdown - The revenue from ophthalmic products was CNY 74.61 million, accounting for 48.70% of the main business revenue, down 52.85% year-on-year [16]. - The revenue from the aesthetic and wound care products dropped significantly, with a decline of 63.69% year-over-year, totaling CNY 21.47 million [17]. - The orthopedic products revenue decreased by 48.87% year-over-year, amounting to CNY 26.09 million [17]. - The company's operating revenue for the first quarter was CNY 153.61 million, a decrease of CNY 158.68 million or 50.81% compared to the same period last year [13]. Cash Flow - The cash flow from investment activities was negative CNY 83.97 million, a decrease of 408.66% year-over-year [20]. - The company reported a net cash outflow from operating activities of CNY -54,461,823.95 in Q1 2020, compared to a positive cash flow of CNY 4,031,326.33 in Q1 2019 [35]. - The company experienced a net decrease in cash and cash equivalents of -72,714,182.45 RMB in Q1 2020, contrasting with an increase of 87,688,044.16 RMB in Q1 2019 [37]. Expenses - Research and development expenses accounted for 18.46% of operating revenue, an increase of 10.65 percentage points compared to the previous year [5]. - The company's financial expenses increased by CNY 24.73 million, primarily due to increased interest income and foreign exchange gains from the depreciation of the British pound against the US dollar [14]. - The company's tax expenses decreased by 115.05% to CNY -1.67 million, mainly due to losses incurred during the reporting period [15]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,099 [7]. - The largest shareholder, Jiang Wei, held 44,449,000 shares, representing 24.99% of the total shares [7].

Financial Performance - The company achieved total revenue of RMB 1,604.33 million in 2019, an increase of RMB 45.88 million or 2.94% compared to 2018[56]. - The net profit attributable to shareholders was CNY 370,778,791.81, a decrease of 10.56% compared to CNY 414,540,417.19 in the previous year[15]. - The company's total assets increased by 38.67% to CNY 6,151,869,396.17 at the end of 2019, up from CNY 4,436,352,586.66 in 2018[15]. - The basic earnings per share decreased by 12.36% to CNY 2.27 in 2019, down from CNY 2.59 in 2018[16]. - The overall gross margin for the company was 77.28%, slightly down from 78.51% in 2018, primarily due to a decrease in the revenue share of high-margin hyaluronic acid products[57]. - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 35,745.00 million, a decrease of 4.96% compared to the previous year[90]. Dividend Policy - The company plans to distribute a cash dividend of RMB 7.00 per 10 shares, totaling RMB 124,491,710, which accounts for 33.58% of the net profit attributable to shareholders for 2019[5]. - The company does not plan to increase capital reserves or issue bonus shares for the 2019 fiscal year[5]. - The company's cash dividend policy stipulates a minimum cash dividend ratio of 80% for mature stages without major capital expenditure plans[199]. Audit and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[4]. - The board of directors and senior management have confirmed the accuracy and completeness of the financial report[4]. - The company has not reported any significant omissions or misleading statements in the annual report[2]. - The company has confirmed that there are no violations of decision-making procedures regarding external guarantees[5]. Research and Development - The company's R&D investment for the reporting period was CNY 116,076,024.05, representing 7.24% of total revenue[40]. - R&D expenses increased by CNY 20,706,300, a growth of 21.71% compared to 2018, primarily due to increased investment in ophthalmology and medical beauty products[41]. - The company has established a comprehensive R&D project management system and emphasizes collaboration with renowned universities and research institutions[33]. - The company has 263 R&D personnel, accounting for 19.66% of the total workforce[40]. - The company is focusing on expanding its product offerings in the ophthalmology sector, with multiple projects in various stages of development and regulatory approval[42][43]. Market Position and Share - The company achieved a market share of 46.87% in the ophthalmic viscoelastic device market, maintaining the leading position for 12 consecutive years[31]. - The market share for the recombinant human epidermal growth factor product "Kanghesu" expanded to 20.39%, securing the second position in the market[31]. - The orthopedic joint cavity viscoelastic supplement product held a market share of 39.67%, also maintaining the leading position for 5 consecutive years[31]. - The company maintained a market share of 48.85% in the anti-adhesion product sector, remaining the largest manufacturer in China for twelve consecutive years[79]. Investment and Acquisitions - The company completed its IPO on the Sci-Tech Innovation Board on October 30, 2019, raising a total of CNY 1,588.29 million, netting CNY 1,529.27 million for the "Shanghai Haohai Biomedical International Pharmaceutical R&D and Industrialization Project"[59]. - The company has made equity investments totaling 12,724.15 million RMB during the reporting period, a decrease of 72.36% compared to the previous year[162]. - The company acquired 100% of ODC on April 25, 2019, which had a negative net asset value of -484.29 million RMB and a net loss of -443.59 million RMB since acquisition[187]. Risks and Challenges - The company has detailed various risk factors that may affect its operations in the report[3]. - The company faced risks from intensified market competition and potential regulatory changes in the pharmaceutical industry, which could impact financial performance[94]. - The company reported a net cash flow from operating activities of RMB 348,910,880.12, a decline of 10.83% compared to the previous year[98]. Product Development and Innovation - The new generation of high oxygen-permeable contact lens material "Optimum Infinite" has been approved by the FDA, boasting an oxygen permeability of over 180 Barrer, making it one of the highest globally[38]. - The company is developing a new type of intelligent drug release material with a total investment of CNY 1.30 billion, aiming for product approval in the near future[46]. - The company is advancing the development of new products in the fields of ophthalmology, plastic surgery, and orthopedics, including a new sodium hyaluronate injection and animal-derived hemostatic agents[137]. Sales and Marketing - The company has established a nationwide marketing network with over 2,000 distributors, covering all provinces and regions in China and approximately 70 countries globally[156]. - The sales model for the company showed that distribution accounted for 52.70% of total revenue, while direct sales contributed 47.30%[84]. - The company is focusing on integrating the ophthalmic cataract treatment business and optimizing marketing channels, supported by national key R&D programs[65].